Physician profile
Temidayo Ayotomiwa Abe
NPI 1366947798
$112,741.24
in general payments reported to CMS, 2019-2025
12 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,624 · 2023: $118 · 2024: $4,637 · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $100K · Travel and Lodging: $6,407 · Food and Beverage: $4,549 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $100,000.00 |
| Travel and Lodging | $6,407.36 |
| Food and Beverage | $4,549.18 |
| Education | $161.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100,000.00 | 2025 | |
| Medtronic, INC. | $5,104.42 | 2024-2025 | Evera Mri Xt Dr Surescan, Micra |
| Abbott Laboratories | $3,597.97 | 2022-2024 | Gallant |
| Medical Device Business Services, INC. | $1,329.11 | 2024 | Carto 3 |
| Biosense Webster, INC. | $1,070.04 | 2025 | Carto 3 |
| Biotronik INC. | $842.65 | 2025 | Acticor 7 Vr-T Dx |
| Amgen INC. | $239.81 | 2023-2024 | Repatha |
| Irhythm Technologies, INC. | $232.95 | 2024 | Zio Xt Patch, Zio Monitor |
| Novo Nordisk INC | $127.36 | 2024 | |
| Chiesi USA, INC. | $100.44 | 2025 | Kengreal |
| Janssen Scientific Affairs, LLC | $77.61 | 2024 | |
| Boston Scientific Corporation | $18.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temidayo Abe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.